Prime Medicine (PRME) Return on Sales (2024 - 2026)

Prime Medicine posted quarterly Return on Sales of 0.58% for Q1 2026, down 22.0% year-on-year from 0.74% in Q1 2025, and down 2.24% on a QoQ basis from 0.57% in Q4 2025.

Prime Medicine (PRME) has 3 years of Return on Sales data on file, last reported at 0.58% in Q1 2026.

  • For the quarter ending Q1 2026, Return on Sales fell 22.0% year-over-year to 0.58%; the trailing twelve-month figure through Mar 2026 stood at 0.5% (up 2.0% YoY), and the FY2025 full-year result was 0.44%, up 22.0% from the prior year.
  • Return on Sales for Q1 2026 stood at 0.58%, down from 0.57% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.19% in Q4 2024 and bottomed at 3.68% in Q2 2024.
  • The 3-year median for Return on Sales is 0.57% (2025), against an average of 1.06%.
  • Peak annual rise in Return on Sales reached 321 bps in 2025, while the deepest fall reached 37 bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 0.19% in 2024, then plunged by 193 bps to 0.57% in 2025, then fell by 2 bps to 0.58% in 2026.
  • The last three Return on Sales figures came in at 0.58% (Q1 2026), 0.57% (Q4 2025), and 0.43% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.00%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.00%
7 Evaxion A 62.56 Bn 62.54 Bn - 0.00%
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.00%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.00%
10 Prime Medicine 601.24 Mn 601.24 Mn - -0.58%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.58%
Dec 31, 2025 -0.57%
Sep 30, 2025 -0.43%
Jun 30, 2025 -0.47%
Mar 31, 2025 -0.36%
Dec 31, 2024 -0.19%
Sep 30, 2024 -2.51%
Jun 30, 2024 -3.68%
Mar 31, 2024 -0.77%